Skip to content

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Relapsed or refractory multiple myeloma (MM) and must:

1. have documented disease progression during or after their last myeloma therapy
2. be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM
* Must have measurable disease
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
* Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP)

Exclusion Criteria:

* Known active or history of central nervous system (CNS) involvement of MM
* Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis.
* Impaired cardiac function or clinically significant cardiac disease
* Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)
* For Part 1: received prior therapy with CC-92480
* For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
* Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment
* Received any of the following within 14 days prior to initiating study treatment:

1. Plasmapheresis
2. Major surgery
3. Radiation therapy other than local therapy for myeloma associated bone lesions
4. Use of any systemic anti-myeloma drug therapy
* Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment
* COVID-19 vaccine within 14 days prior to C1D1

Other protocol-defined inclusion/exclusion criteria apply

Study Location

University Health Network UHN - Princess Margaret Hospital PMH
University Health Network UHN - Princess Margaret Hospital PMH
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Donna Reece, Site 0004

4169462824
Alberta Health Services AHS - Foothills Medical Centre FMC
Alberta Health Services AHS - Foothills Medical Centre FMC
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Nizar Bahlis, Site 0009

14039441880
University of Alberta - Cross Cancer Institute
University of Alberta - Cross Cancer Institute
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Michael Chu, Site 0008

7804328757
Study Sponsored By
Bristol-Myers Squibb
Participants Required
More Information
Study ID: NCT05372354